Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

References

• Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5. doi:10.1186/s13223-020-0403-9403
   PubMed Web of Science ®Google Scholar
• Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124(2):118–134. doi:10.1016/j.anai.2019.11.014
   PubMed Web of Science ®Google Scholar
• Leonardi A, Castegnaro A, Valerio AL, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol. 2015;15(5):482–488. doi:10.1097/ACI.0000000000000204
   PubMed Web of Science ®Google Scholar
• Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;(6):CD009566. doi:10.1002/14651858.CD009566.pub2
   PubMed Web of Science ®Google Scholar
• Leonardi A, Silva D, Perez Formigo D, et al. Management of ocular allergy. Allergy. 2019;74(9):1611–1630. doi:10.1111/all.13786
   PubMed Web of Science ®Google Scholar
• Torkildsen G, Narvekar A, Bergmann M. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol. 2015;9:1703–1713. doi:10.2147/OPTH.S83263
   PubMedGoogle Scholar
• Meier E, Narvekar A, Iyer GR, et al. Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. OPTH. 2017;11:669–681. doi:10.2147/OPTH.S126690
   Google Scholar
• Meier EJ, Torkildsen GL, Gomes PJ, Jasek MC. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clin Ophthalmol. 2018;12:2617–2628. doi:10.2147/OPTH.S185835opth-12-2617
   PubMed Web of Science ®Google Scholar
• Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. Clin Ophthalmol. 2019;13:403–413. doi:10.2147/OPTH.S186092opth-13-403
   PubMed Web of Science ®Google Scholar
• Ayyappanavar S, Sridhar S, Kumar K, et al. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Indian J Ophthalmol. 2021;69(2):257–261. doi:10.4103/ijo.IJO_2083_20
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. doi:10.1111/all.13317
   PubMed Web of Science ®Google Scholar
• MHRA. Summary of product characteristics Ilaxten 10 mg orodispersible tablets, bilastine 2018; 2018. Available from: https://mhraproductsproduction.blob.core.windows.net/docs/2f799931ac3572bd33b801e5b15e6168c95b156a. Accessed 15, May 2022.
   Google Scholar
• Church MK, Tiongco-Recto M, Ridolo E, Novak Z. Bilastine: a lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020;36(3):445–454. doi:10.1080/03007995.2019.1681134
   PubMed Web of Science ®Google Scholar
• Okubo K, Gotoh M, Asako M, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66(1):97–105. doi:10.1016/j.alit.2016.05.014
   PubMed Web of Science ®Google Scholar
• Togawa M, Yamaya H, Rodriguez M, Nagashima H. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clin Drug Investig. 2016;36(12):1011–1021. doi:10.1007/s40261-016-0447-2
   PubMed Web of Science ®Google Scholar
• Sastre J, Mullol J, Valero A, Valiente R. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin. 2012;28(1):121–130. doi:10.1185/03007995.2011.640667
   PubMed Web of Science ®Google Scholar
• Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375–385. doi:10.1111/1346-8138.13644
   PubMed Web of Science ®Google Scholar
• Ochoa D, Román M, Belmonte C, et al. Pharmacokinetics and safety of a bilastine once-daily, preservative-free, ophthalmic formulation. Adv Ther. 2021;38(7):4070–4081. doi:10.1007/s12325-021-01801-y
   PubMed Web of Science ®Google Scholar
• Torrens Prat I, Gonzalo A, Ganza Á, Hernández G, Zazpe A. Ocular biodistribution of once‐daily bilastine eye drops reveals highest levels in conjunctiva up to 24 hours post‐administration. Acta Ophthalmol. 2022;100(S267):1755–3768. doi:10.1111/j.1755-3768.2022.182
   Google Scholar
• Gomes PJ, Ciolino JB, Arranz P, Hernández G, Fernández N. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: a dose-finding study. J Investig Allergol Clin Immunol. 2022;33(4). doi:10.18176/jiaci.0800
   PubMed Web of Science ®Google Scholar
• Allaire C, Siou-Mermet R, Bassols A. Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test. J Fr Ophtalmol. 2012;35(7):491–498. doi:10.1016/j.jfo.2011.08.016
   PubMed Web of Science ®Google Scholar
• Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol. 2001;131(6):691–698. doi:10.1016/S0002-9394(00)00947-8
   PubMed Web of Science ®Google Scholar
• Greiner JV, Mundorf T, Dubiner H, et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol. 2003;136(6):1097–1105. doi:10.1016/S0002-9394(03)00708-6
   PubMed Web of Science ®Google Scholar
• Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. Allergy. 1998;53(9):857–862. doi:10.1111/j.1398-9995.1998.tb03991.x
   PubMed Web of Science ®Google Scholar
• Melamed J, Schwartz RH, Blumenthal MN, Zeitz HJ. Efficacy and safety of nedocromil sodium 2% ophthalmic solution b.i.d. in the treatment of ragweed seasonal allergic conjunctivitis. Allergy Asthma Proc. 2000;21(4):235–239. doi:10.2500/108854100778248863
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310. doi:10.1016/s0149-2918(01)80109-0
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SF, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307–2335. doi:10.1016/s0149-2918(03)80222-9
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36(2):361–368. doi:10.1038/s41433-021-01668-x
   PubMed Web of Science ®Google Scholar